MedTrace Logo

Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

NCT05702229 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 163

Last updated 2026-05-14

No results posted yet for this study

Summary

This is a Phase II, open-label, multi-drug, multi-centre study designed to assess the efficacy, safety, tolerability, pharmacokinetics, and immunogenicity of novel combination therapies in participants with locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma.

Conditions

Interventions

DRUG

Rilvegostomig

an anti PD-1 and anti-TIGIT bispecific antibody; IV infusion

DRUG

Volrustomig

an anti PD-1 and anti CTLA-4 bispecific antibody; IV infusion

DRUG

FOLFOX

5-fluorouracil oxaliplatin, leucovorin (levoleucovorin when locally preferred and available)

DRUG

XELOX

capecitabine and oxaliplatin

DRUG

AZD0901

an anti Claudin18.2 ADC; IV infusion

DRUG

5-Fluorouracil

5-FU, IV infusion

DRUG

Capecitabine

Oral take

Sponsors & Collaborators

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-16
Primary Completion
2027-11-30
Completion
2029-05-31
FDA Drug
Yes

Countries

  • United States
  • China
  • Japan
  • South Korea
  • Spain
  • Taiwan
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05702229 on ClinicalTrials.gov